Key facts
- It has raised $21.8M; the latest was Grant ($14.1M) in Jul 2025.
- Notable investors include MassChallenge, London & Partners., Meltwind Advisory, Jonathan Milner, Starbloom Capital — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for LIfT BioSciences
- ·The full record, as it builds
Funding rounds
No funding rounds for LIfT BioSciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LIfT BioSciences
Developer of a biotech platform designed for CAR neutrophil cell therapy that helps overcome the limitations of current therapies in solid tumors. The company's platform offers immunomodulatory alpha neutrophils (IMANs) that turn the tumor microenvironment and recruit the rest of the immune system to destroy the lasting immunity by using stem cells, which is a proprietary media and genetic engineering, enabling healthcare providers to use CAR-IMAN cells to give patients potentially the cancer-killing ability they naturally possess.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2014
- Employees
- 19
- Website
- liftbiosciences.com/
- Ownership
- Privately Held (backing)
LIfT BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LIfT BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LIfT BioSciences in its N-PORT filings yet. We sweep new filings monthly.